12

AIA Trial Statistics October 2017 - United States Patent ... Statistics IPR, PGR, CBM Patent Trial and Appeal Board October 2017

  • Upload
    vannga

  • View
    215

  • Download
    0

Embed Size (px)

Citation preview

Trial StatisticsIPR, PGR, CBMPatent Trial and Appeal Board October 2017

IPR7,07492%

CBM5297%

PGR821%

7,685 Total

3

Petitions by Trial Type (All Time: 9/16/12 to 10/31/17)

Trial types include Inter Partes Review (IPR), Post Grant Review (PGR), and Covered Business Method (CBM).

4

Petitions Filed by Technology in FY18(FY18 to date: 10/1/17 to 10/31/17)

Electrical/Computer70

54%

Mechanical & Business Method

3326%

Chemical6

5%

Bio/Pharma19

15%

Design0

0%

128 Total

10

0 0

5

0

5

10

Oct-16 Oct-17CBM

(5 CBMs in FY18)

0

74 4 4

0

5

10

Oct-16 Oct-17PGR

(4 PGRs in FY18)

237

116 119 124 119

100125150175200225250

Oct-16 Oct-17IPR

(119 IPRs in FY18)

5

Petitions Filed by Month (October 2017 and Previous 12 Months: 10/1/16 to 10/31/17)

NTE

NTE

NTENTE NTE

86% 82% 86% 87%

64%71%

85% 85% 83% 87%

49%63%

35% 38% 37%

Pre Post Pre Post Pre Post Pre Post Pre Post

Bio/Pharma Chemical Design Electrical/Computer Mechanical &Business Method

6

Preliminary Response Filing RatesPre- and Post-Rule To Allow New Testimonial Evidence (NTE)(All Time: 9/16/12 to 10/31/17)

The rule to allow new testimonial evidence was effective May 2, 2016.

191

664

1,012 1,011 955

8729223

469 496 557

90

87%

75%68% 67% 63%

49%

0

200

400

600

800

1,000

1,200

1,400

1,600

1,800

2,000

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

FY13 FY14 FY15 FY16

Instituted Denied

7

FY17

Institution Rates(FY13 to FY18: 10/1/12 to 10/31/17)

Institution rate for each fiscal year is calculated by dividing petitions instituted by decisions on institution (i.e., petitions instituted plus petitions denied). The outcomes of decisions on institution responsive to requests for rehearing are excluded.

FY18

69% (997 of 1,441)

69% (2,311 of 3,364)

41% (17 of 41)

66% (258 of 388)

61% (337 of 550)

Mechanical &Business Method

Electrical/Computer

Design

Chemical

Bio/Pharma

8

Institution Rates by Technology(All Time: 9/16/12 to 10/31/17)

Institution rate for each technology is calculated by dividing petitions instituted by decisions on institution (i.e., petitions instituted plus petitions denied). The outcomes of decisions on institution responsive to requests for rehearing are excluded.

9

Settlement rate for each year is calculated by dividing pre-institution settlements by the sum of proceedings instituted, denied institution, dismissed, terminated with a request for adverse judgment, and settled before decision on institution.

Settlements

Settlement Rate

Pre-Institution Settlements(FY13 to FY18: 10/1/12 to 10/31/17)

23

127

291242 249

18

9%

12%

16%

14% 14%

9%

0%

2%

4%

6%

8%

10%

12%

14%

16%

18%

20%

FY13 FY14 FY15 FY16 FY17 FY18

10

Settlement rate for each year is calculated by dividing post-institution settlements by proceedings terminated post-institution (i.e., settled, dismissed, terminated with a request for adverse judgment, and final written decision), excluding joined cases.

Settlements

Settlement Rate

Post-Institution Settlements(FY13 to FY18: 10/1/12 to 10/31/17)

18

110

212 194 187

6

90%

40%29% 22% 22%

11%

-75%

-55%

-35%

-15%

5%

25%

45%

65%

85%

FY13 FY14 FY15 FY16 FY17 FY18

7,685

3,939

1,817

850950 72 29

1,845 367744

727 38 246

All Claims: 1,181 (65%)Some Claims: 290 (16%)

No Claim: 346 (19%)

Peti

tion

s

Ope

n Pr

e-In

stit

utio

n

Sett

led

Dis

mis

sed

Req.

Adv

.Ju

dgm

ent

Den

ied

Inst

itut

ed

Join

ed

Ope

n Po

st-

Inst

itut

ion

Sett

led

Dis

mis

sed

Req.

Adv

.Ju

dgm

ent

Fina

l Wri

t.D

ecis

ions

Instituted Claims Unpatentable

11

Status of Petitions(All Time: 9/16/12 to 10/31/17)

These figures reflect the latest status of each petition. The outcomes of decisions on institution responsive to requests for rehearing are incorporated. Once joined to a base case, a petition remains in the Joined category regardless of subsequent outcomes.